Another vital sub-segment is homecare settings, which have gained prominence due to the rising preference for outpatient care and patient autonomy
Without specific proof as to the exact cause of why a GLP-1 could cause a higher risk of developing NAION, we can hypothesize a bit and suggest hypovolemia and dehydration from perhaps weight loss, especially if the patient is getting a medication for hypertension and the weight loss has reduced the need for the hypertensive agent and thus the patient develops hypotension
(Ozempic) GLP-1 62%
If approved, Retatrutide could redefine obesity management by combining substantial weight reduction with meaningful metabolic improvements
The way a program handles dose increases, side effects, and follow-up support can shape how manageable treatment feels over time
Any savings on health spending because of obesity drugs may take many years and may not accrue to the Medicaid program if individuals experience shifts in coverage, so states may not be factoring long-term savings into coverage decisions